Enzyme-linked immunosorbent assay (ELISA) for the quantitative determination of free Ranibizumab (Lucentis®) in aqueous humour. The Assay Genie Ranibizumab ELISA has been specially developed for the quantitative analysis of free Ranibizumab in aqueous humour and is for research use only.

Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and samples are incubated in the microtitre plate coated with the reactant for ranibizumab (Lucentis®). After incubation, the wells are washed. A horse radish peroxidase (HRP) conjugated probe is added and binds to ranibizumab captured by the reactant on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. The colour developed is proportional to the amount of ranibizumab in the sample or standard. Results of samples can be determined directly using the standard curve.

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline (tetracycline is not detectable in the final product).

Ranibizumab is marketed under the name Lucentis®. It is indicated for the treatment of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema. Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF110. The binding of ranibizumab to VEGF-A prevents the interaction of VEGFA with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab is a VEGF-A antagonist that binds to and inhibits the biologic activity of active forms of human VEGF-A, including the cleaved form (VEGF110). VEGF-A has been shown to cause neovascularization (angiogenesis) and an increase in vascular permeability, which is thought to contribute to the progression of the neovascular form of age-related macular degeneration (AMD).

Following monthly intravitreal injections, maximum aqueous humour concentrations are minimal around 0.3 ng/mL to 2.36 ng/mL. The most common toxic effects to the eye are eye pain, vitreous floaters, increased intraocular pressure, conjunctival hemorrhage, intraocular inflammation, and foreign body sensation. Also, arterial thromboembolic events have occurred in patients.

LUCENTIS is a trademark of GENENTECH, INC